Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: A detection device may be attached to or secured in a vehicle component, with which physical and/or chemical values can be detected. The device may include of at least one of the following: a detection unit placed or formed on a first mount for detecting a physical and/or chemical value, wherein the first mount has at least one mounting interface for attaching the first mount to the vehicle component; and a functional unit to which the detection unit is dedicated, placed or formed on or in a second mount, wherein the second mount has at least one connecting interface for connecting the second mount to the first mount.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Methods and apparatus, including computer program products, implementing and using techniques for converting a target file into a multimedia presentation. A target file including text is received. A class of the target file is identified based on characteristics of the target file. A multimedia presentation is created that contains speech rendered from a portion of the text, additional text, wherein the portion of the text is selected in accordance with a template programmed with content and logic for the identified class, a visual representation of the document, and one or more manipulations of the visual representation defined in accordance with the content and logic of the template. In response to a user command to run the multimedia presentation, the speech, visual representation, and/or the manipulations are output in accordance with the logic of the template.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Described herein are selective inhibitors of FGFR4, pharmaceutical compositions including such compounds, and combinations with other therapeutic agents, such as CDK inhibitors (e.g., CDK4/6 inhibitors), and methods of using such combinations.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The present invention relates to methods for treating a dalotuzumab responsive cancer, in a patient, comprising determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; administering, to said patient, a therapeutically effective amount of dalotuzumab. The invention also relates to methods for assessing neoplastic cells, selecting patients, selecting therapies as well as diagnostic methods.

Abstract: A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed.

Abstract: Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment with an IGF-1R inhibitor if the cells from the patient are determined to be sensitive. The determination is based upon either the expression levels of wild type LKB1 in the patient sample wherein a low level of expression of the protein or the gene encoding the biomarker protein is predictive of a favorable outcome to an IGF-1R targeted therapy or detecting the presence of a loss of function mutant LKB1 in the sample, wherein presence of the mutant is predictive of a favorable outcome.

Abstract: The present invention relates to a method of treating cancer by administering an IGF-1R specific antibody in combination with an anti-cancer agent exemplified by an Akt pathway inhibitor. The first and second amounts together comprise a therapeutically effective amount.

Abstract: The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.

Abstract: A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed.

Abstract: The invention relates to the identification and use of gene expression profiles with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. The same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. The methods may further comprise selecting a treatment based on the classifying step.

Abstract: An electronic method for obtaining bids for investments in guaranteed investment contracts (and similar investment products) and investments purchased for a yield restricted defeasance escrow, includes the steps of providing an investor intermediary computer having a digital data store, inputting data into the digital data store representing the bid specifications of the investment, and providing a digital input/output electronic two-way communications link allowing communication between the investor intermediary computer and a plurality of investment provider computers by means of an electronic two-way communications link.

Abstract: Human TBK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of TTBK are provided.

Abstract: Human PRKC genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PRKC are provided.